90 Chapter 4 Table 3. Risk of cognitive decline for continuous N biomarkers Biomarker Model 1 Model 2 Model 3 Model 4 T-tau -0.17 (0.04)a,b -0.15 (0.04)a,b -0.14 (0.04)a,b Aβ -0.11 (0.04)a,b P-tau MTA -0.06 (0.04) -0.04 (0.05) -0.04 (0.05) -0.04 (0.04) Aβ -0.14 (0.04)a,b -0.12 (0.04)a,b P-tau -0.12 (0.04)a,b HV -0.11 (0.04)a,b -0.13 (0.05)a,b -0.13 (0.04)a,b -0.13 (0.04)a,b Aβ -0.13 (0.04)a,b -0.12 (0.04)a,b P-tau -0.11 (0.04)a,b NfL -0.06 (0.05) -0.05 (0.06) -0.01 (0.06) -0.02 (0.06) Aβ -0.11 (0.05)a -0.09 (0.05) P-tau -0.16 (0.05)a,b GFAP -0.15 (0.05)a,b -0.14 (0.06)a,b -0.11 (0.06) -0.10 (0.06) Aβ -0.08 (0.05) -0.06 (0.05) P-tau -0.16 (0.05)a,b Abbreviations: Aβ = β-amyloid; GFAP = glial fibrillary acidic protein; HV = hippocampal volume; MTA = medial temporal atrophy; NfL = neurofilament light; p-tau = phosphorylated tau; t-tau = total tau. Results shown are β (SE) as estimated by linear mixed models. Outcome is MiniMental State Examination score. Predictors: model 1: neurodegeneration, time, neurodegeneration*time; model 2: variables included in model 1, age, sex, age*time and sex*time; model 3: variables included in model 2, CSF Aβ and Aβ *time; model 4: variables included in model 3, CSF p-tau and p-tau*time). In models with MTA and HV, scanner type was additionally added as covariate. βs represent the interaction between neurodegeneration biomarker and time, which corresponds to the cognitive slope. P-tau, t-tau, NfL and GFAP were log transformed, Aβ and hippocampal volume were inverted, all biomarkers were z-transformed. T-tau was not entered in model 4 due to collinearity between t-tau and p-tau. a p <0.05. b False discovery rate-corrected p <0.05

RkJQdWJsaXNoZXIy MjY0ODMw